BET bromodomain inhibitors act, among others, by inhibiting NF-κB signaling and have already shown their potential in increasing therapeutic efficacy in MPN and might be particularly effective in SMF [52]. The gene discussed is NFKB1; the disease is myeloproliferative neoplasm.